ZIOPHARM Oncology (NASDAQ:ZIOP) pushes higher after presenting data on the treatment of recurrent glioblastoma as part of the ASCO Virtual Scientific Program.
“According to most recent data, even with the best
available therapies, median overall survival for unifocal rGBM patients
appears to be 6-12 months. We are therefore heartened by the collection
of data presented at ASCO across our three studies, which demonstrate
survival benefits beyond a year supported by imaging studies showing
tumor regression and biopsies revealing that Ad+V administration turns
‘cold’ tumors ‘hot’ by recruiting T cells into the tumor. We look
forward to continuing to report follow-up monotherapy and combination
phase 1 data, as well as initial data from the ongoing phase 2 study of
Ad+V in combination with Libtayo, which is nearing completion of
enrollment.”
Shares of ZIOP are up 4.34% premarket on volume of 6.2K.
Previously: All eyes on ASCO (May 29)
https://seekingalpha.com/news/3578640-ziopharmplus-4-after-asco-presentation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.